AbbVie (ABBV) 8-K Guidance Including the Impact of Acquired IPR&D and Milestones Expense Incurred During the Second Quarter of 2022

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense Incurred During the Second Quarter of 2022

(Unaudited) (In millions, except per share data)

	Quarter Ended June 30, 2022						Full-Year Ended December 31, 2022
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q2 2022 acquired IPR&D and milestones expense	$	—	$	3.38	$	3.42	$	145	$	13.92	$	14.12
Q2 2022 acquired IPR&D and milestones expense	269		(0.14)		(0.14)		269		(0.14)		(0.14)
Guidance including Q2 2022 acquired IPR&D and milestones expensea	$	269	$	3.24	$	3.28	$	414	$	13.78	$	13.98

a    The Company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2022, as both cannot be reliably forecasted.

    1